Chronic News and Research

RSS

Cocrystal receives $733,438 in grants from QTDP program

Cocrystal Discovery, Inc., a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases, announced today that it has received $733,438 in grants from the Qualified Therapeutic Discovery Project (QTDP) administered under section 48D of the Internal Revenue Code.

4 Nov 2010

Aduro receives $442,000 grant under QTDP program to support Listeria-based immunotherapy platform

Aduro BioTech announced today that it has been awarded two cash grants totaling approximately $442,000 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

EDP Biotech receives $244,000 grant under QTDP program for colon cancer blood test

EDP Biotech Corporation was awarded a $244,000 grant from the federal government under the Qualifying Therapeutic Discovery Project program as a result of the company's work in the development of their ColoMarker test, an early detection blood test for colon cancer.

4 Nov 2010

Aeolus receives $489,000 grant under QTDP program for two lead compounds

Aeolus Pharmaceuticals, Inc. today announced that it has been awarded a total of approximately $489,000 under the Qualifying Therapeutic Discovery Grant Program (QDTP) administered by the Internal Revenue Service and the Department of Health and Human Services.

4 Nov 2010

New cyber-database enables access to information on lymphedema

Lymphedema is a chronic condition that causes swelling of the limbs and affects physical, mental and social health. It commonly occurs in breast cancer survivors and is the second-most dreaded effect of treatment, after cancer recurrence. Every day, researchers throughout the world learn more about the condition and how it can be treated. Now, University of Missouri researchers are developing a place in cyberspace where relevant and timely information can be easily stored, searched, and reviewed from anywhere with the goal of improving health care through the availability of up-to-date, evidence-based research.

4 Nov 2010

Quick-Med Technologies awarded $244,000 QTDP grant to advance antimicrobial technology for wound care

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today it has been awarded by the U.S government under Qualifying Therapeutic Discovery Project (QTDP) to advance the development of the company's NIMBUS® technology for wound dressings and wound drains.

4 Nov 2010

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Spectrum Pharmaceuticals, Inc. a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it has been awarded grants totaling $977,900 under the Qualifying Therapeutic Discovery Project (QTDP) Program administered under section 48D of the Internal Revenue Code.

4 Nov 2010

Single injection of morphine to fight persistent pain reduces testosterone level: Research

A single injection of morphine to fight persistent pain in male rats is able to strongly reduce the hormone testosterone in the brain and plasma, according to a new paper published in Molecular Pain.

4 Nov 2010

Affymax receives $244,479.25 in funding under QTDP program

Affymax, Inc. today announced that it has been awarded $244,479.25 in funding under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program established under Section 48D of the Internal Revenue Code.

4 Nov 2010

PolyMedix receives $488,958 grants under QTDP program

PolyMedix, Inc. a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

One-third of breast cancer survivors rate breast-conserving treatments as fair

A third of breast cancer survivors who received the breast-conserving treatments lumpectomy and radiation rate the appearance of their post-treatment breast as only "fair" or "poor" in comparison to their untreated breast, according to a new University of Pennsylvania School of Medicine study that will be presented today at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.

3 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

Questcor announces launch of H.P. Acthar Gel for infantile spasms

Questcor Pharmaceuticals, Inc. today announced that the commercial launch is now underway for H.P. Acthar® Gel (repository corticotropin injection) as monotherapy for the treatment of Infantile Spasms (IS) in infants and children under the age of two years. This new Acthar indication was approved by the U.S. Food and Drug Administration (FDA) on October 15, 2010.

3 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

InVivo receives $244,000 in grant funding under QTDP program

InVivo Therapeutics a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has been awarded $244,000 in grant funding as part of the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

3 Nov 2010

IU's cost-saving model of home-based care management for low-income older adults earns recognition

A model program developed at Indiana University to provide care to low-income older adults in their homes has earned recognition for its effective approach and cost-saving benefits in a leading national medical journal.

3 Nov 2010

New primary care models needed to improve care and outcomes for older adults

In an article published in November 3 edition of Journal of the American Medical Association (JAMA), Chad Boult, MD, MPH, MBA, professor of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health, calls for key improvements to primary care in order to improve the health of the nation's most costly patients-older adults with multiple chronic conditions.

3 Nov 2010

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Immune Network Ltd. a company in the business of discovery and development of immune-based therapies, today announced that patient enrollment will be completed next week for the company's future partner Immunitor's Phase 2b imm01 trial of V5 immunotherapy in 120 patients with tuberculosis.

3 Nov 2010

Veterans deserve best health care coverage

The nation pauses to honor its veterans on November 11 for their patriotism, love of country, and willingness to serve and sacrifice for the common good. Naturally, we want our veterans to be taken care of, especially when it comes to their health. Those who have served their country through the United States military have several options when it comes to their health care coverage.

3 Nov 2010

Health Affairs recognizes U-M leadership in implementing Value-Based Insurance Design

Value-Based Insurance Design - a concept created at the University of Michigan and incorporated in the nation's new health care reform law - is the focus of an upcoming national policy journal.

3 Nov 2010

Chronic News and Research

Cocrystal receives $733,438 in grants from QTDP program

Aduro receives $442,000 grant under QTDP program to support Listeria-based immunotherapy platform

EDP Biotech receives $244,000 grant under QTDP program for colon cancer blood test

Aeolus receives $489,000 grant under QTDP program for two lead compounds

New cyber-database enables access to information on lymphedema

Quick-Med Technologies awarded $244,000 QTDP grant to advance antimicrobial technology for wound care

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Single injection of morphine to fight persistent pain reduces testosterone level: Research

Affymax receives $244,479.25 in funding under QTDP program

PolyMedix receives $488,958 grants under QTDP program

One-third of breast cancer survivors rate breast-conserving treatments as fair

Bortezomib reduces inflammation and promotes bone healing in arthritis models

Questcor announces launch of H.P. Acthar Gel for infantile spasms

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

InVivo receives $244,000 in grant funding under QTDP program

IU's cost-saving model of home-based care management for low-income older adults earns recognition

New primary care models needed to improve care and outcomes for older adults

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Veterans deserve best health care coverage

Health Affairs recognizes U-M leadership in implementing Value-Based Insurance Design

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News